Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
0 hedge funds and large institutions have $0 invested in Biostage, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 25 closing their positions.
100% less funds holding
Funds holding: 25 → 0 (-25)
100% less capital invested
Capital invested by funds: $773K → $0 (-$773K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 25
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$285K |
| 2 |
BlackRock
New York
|
-$188K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$65K |
| 4 |
Renaissance Technologies
New York
|
-$65K |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$32K |
BSTG Hedge Fund Activity: Q4 2017 in Review
0 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q4 2017, worth a combined $0 — down 100% from $773K a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of BSTG and 0 opened new positions — a net loss of 25 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $285K sold.
- 0 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q4 2017, down from 25 in Q3 2017.
- Funds reported $0 of Biostage, Inc. Common Stock stock for Q4 2017, down 100% quarter-over-quarter.
- 0 funds opened new Biostage, Inc. Common Stock positions in Q4 2017 and 25 closed out, a net change of -25 holders.
- The largest Biostage, Inc. Common Stock seller in Q4 2017 was Vanguard Group, an estimated $285K sold.
Based on aggregated 13F filings for Q4 2017.